tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating
PremiumRatingsBelite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating
2M ago
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress
Premium
Ratings
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress
2M ago
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease
Premium
Company Announcements
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease
2M ago
Belite Bio Advances Tinlarebant Trials with Positive Interim Results
PremiumCompany AnnouncementsBelite Bio Advances Tinlarebant Trials with Positive Interim Results
2M ago
Belite Bio reports Q1 EPS (27c), consensus (37c)
Premium
The Fly
Belite Bio reports Q1 EPS (27c), consensus (37c)
2M ago
Belite Bio reports Q1 EPS (45c), consensus (37c)
Premium
The Fly
Belite Bio reports Q1 EPS (45c), consensus (37c)
2M ago
Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating
PremiumRatingsBelite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating
4M ago
Promising Pipeline and Strategic Advancements: Marc Goodman Recommends ‘Buy’ for Belite Bio, Inc.
Premium
Ratings
Promising Pipeline and Strategic Advancements: Marc Goodman Recommends ‘Buy’ for Belite Bio, Inc.
4M ago
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress
Premium
Company Announcements
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100